Filing Details
- Accession Number:
- 0001596783-21-000125
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-08-30 21:40:18
- Reporting Period:
- 2021-08-26
- Accepted Time:
- 2021-08-30 21:40:18
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1596783 | Catalent Inc. | CTLT | Pharmaceutical Preparations (2834) | 208737688 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1612357 | Aristippos Gennadios | C/O Catalent, Inc. 14 Schoolhouse Road Somerset NJ 08873 | President Softgel & Oral Tech | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-08-26 | 8,008 | $0.00 | 59,743 | No | 4 | A | Direct | |
| Common Stock | Disposition | 2021-08-27 | 171 | $130.29 | 59,572 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-08-27 | 2,091 | $131.20 | 57,481 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- Received upon the achievement of the fiscal 2019-21 performance-based vesting criteria set forth in certain incentive compensation held by the reporting person under the Issuer's long-term incentive plan.
- Includes restricted stock units.
- This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in order to cover tax withholding obligations in connection with the vesting of performance share units received pursuant to the Issuer's long-term incentive plan. No shares were withheld by or surrendered to the Issuer.
- Volume-weighted average price. These shares were sold in multiple transactions at prices ranging from $129.82 to $130.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- Volume-weighted average price. These shares were sold in multiple transactions at prices ranging from $130.84 to $131.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Billionaire Hedge Funds
